SREBF1 and metabolic dysfunction-associated steatotic liver disease: Moreover, TIIA is an ideal candidate for the treatment of NAFLD because it can inhibit lipogenesis and lipid accumulation by regulating the LXRα/SREBP1 pathway and target PPAR-γ and TLR4 to improve lipid metabolism and oxidative stress [135,136].